

Anton P Porsteinsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2474174/publications.pdf>

Version: 2024-02-01

108
papers

7,246
citations

94433

37
h-index

56724

83
g-index

123
all docs

123
docs citations

123
times ranked

7975
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 81-89.	1.2	9
2	Attitudes Toward Computers Moderate the Effect of Computerized Cognitive Trainings in Oldest-Old Senior Living Center Residents. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 285-294.	1.2	5
3	Point-of-care research in dementia – another arrow in our quiver?. <i>International Psychogeriatrics</i> , 2021, 33, 199-200.	1.0	0
4	Targeting autonomic flexibility to enhance cognitive training outcomes in older adults with mild cognitive impairment: study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 560.	1.6	5
5	Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. <i>SLEEP Advances</i> , 2021, 2, zpab015.	0.2	9
6	Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1324.	9.0	51
7	Aducanumab, gantenerumab, BAN2401, and ALZ-801 – the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 95.	6.2	218
8	Escitalopram for agitation in Alzheimer's disease (Sâ€CITAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. <i>Alzheimer's and Dementia</i> , 2019, 15, 1427-1436.	0.8	28
9	Identify a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer's pathology. <i>Brain Imaging and Behavior</i> , 2019, 13, 53-64.	2.1	12
10	Dementia clinical trial implications of mild behavioral impairment. <i>International Psychogeriatrics</i> , 2018, 30, 171-175.	1.0	55
11	F4 – THE Sâ€CITAD STUDY: TRIAL DESIGN AND METHODS FOR THE Sâ€CITALOPRAM IN AGITATION TRIAL. <i>Alzheimer's and Dementia</i> , 2018, 14, P1384.	0.8	0
12	P1 – THE EFFECTS OF MEMANTINE ADDED TO CHOLINESTERASE INHIBITORS ON NPI BEHAVIORAL DOMAINS: POOLED POST HOC ANALYSIS OF THREE RANDOMIZED CONTROLLED TRIALS IN PATIENTS WITH MODERATE TO SEVERE AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P297.	0.8	1
13	Efficacy and mechanisms of combined aerobic exercise and cognitive training in mild cognitive impairment: study protocol of the ACT trial. <i>Trials</i> , 2018, 19, 700.	1.6	18
14	Temporospatial components of brain ERPs as biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 604-614.	2.4	3
15	Attributable Cost of Dementia: Demonstrating Pitfalls of Ignoring Multiple Health Care System Utilization. <i>Health Services Research</i> , 2018, 53, 5331-5351.	2.0	14
16	Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 450-457.	1.9	31
17	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 689-707.	2.6	15
18	The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 46.	1.6	34

#	ARTICLE	IF	CITATIONS
19	An update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2017, 18, 611-620.	1.8	58
20	The cingulate cortex of older adults with excellent memory capacity. Cortex, 2017, 86, 83-92.	2.4	40
21	[P1â€“052]: CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4 HOMOZYGOTES WITH MILD TO MODERATE ALZHEIMER'S DISEASE (AD) ARE SUSTAINED OVER 130 WEEKS: RESULTS OF A PHASE 3 EXTENSION STUDY. Alzheimer's and Dementia, 2017, 13, P256.	0.8	0
22	[P1â€“069]: OPTIMIZING MEASUREMENT OF AGITATION AND AGGRESSION IN DEMENTIA. Alzheimer's and Dementia, 2017, 13, P264.	0.8	1
23	Cognitive and Neural Effects of Vision-Based Speed-of-Processing Training in Older Adults with Amnesic Mild Cognitive Impairment: A Pilot Study. Journal of the American Geriatrics Society, 2016, 64, 1293-1298.	2.6	80
24	Râ€•and Sâ€•citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. British Journal of Clinical Pharmacology, 2016, 82, 784-792.	2.4	54
25	Insula and Inferior Frontal Gyrus Activities Protect Memory Performance Against Alzheimer's Disease Pathology in Old Age. Journal of Alzheimer's Disease, 2016, 55, 669-678.	2.6	69
26	Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 373-381.	2.6	8
27	P4-209: Longitudinal Functional Decline of Striatum in Mild Cognitive Impairment. , 2016, 12, P1104-P1105.		0
28	Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. American Journal of Psychiatry, 2016, 173, 473-480.	7.2	63
29	Principal components analysis of agitation outcomes in Alzheimer's disease. Journal of Psychiatric Research, 2016, 79, 4-7.	3.1	4
30	Dazed and Confused: Medical Cannabis in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2016, 24, 1004-1006.	1.2	6
31	Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 54, 69-78.	2.6	31
32	Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. Journal of Psychiatric Research, 2016, 74, 17-21.	3.1	41
33	Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. American Journal of Psychiatry, 2016, 173, 465-472.	7.2	77
34	Mental Fatigability and Heart Rate Variability in Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2016, 24, 374-378.	1.2	13
35	ERP C250 shows the elderly (cognitively normal, Alzheimer's disease) store more stimuli in short-term memory than Young Adults do. Clinical Neurophysiology, 2016, 127, 2423-2435.	1.5	4
36	A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 99-109.	1.8	14

#	ARTICLE	IF	CITATIONS
37	Citalopram for the Treatment of Agitation in Alzheimer Dementia. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 59-64.	2.3	8
38	Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2016, 24, 70-80.	1.2	39
39	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. International Psychogeriatrics, 2015, 27, 2059-2067.	1.0	22
40	P2-112: Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: Evidence from the citad study. , 2015, 11, P526-P526.		0
41	O4-09-05: Dextromethorphan/quinidine (AVP-923) for treatment of agitation in patients with Alzheimer's disease: Analysis of week 10 results for patients treated only with AVP-923 versus patients receiving only placebo (NCT01584440). , 2015, 11, P291-P292.		0
42	Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. International Psychogeriatrics, 2015, 27, 7-17.	1.0	244
43	P3-301: Dextromethorphan/quinidine (AVP-923) phase 2 study for treatment of agitation in Alzheimer's disease: Comparing the enrolled agitation sample with the international psychogeriatric association		

#	ARTICLE	IF	CITATIONS
55	O5-06-06: CHANGES IN QTC INTERVAL IN THE CITALOPRAM FOR AGITATION IN ALZHEIMER'S DISEASE (CITAD) RANDOMIZED TRIAL. , 2014, 10, P304-P304.		0
56	O3-06-06: The neuroprotective and neurotrophic agent T-817MA for Alzheimer's disease: Randomized, double-blind, placebo-controlled proof-of-concept trial outcomes. , 2013, 9, P530-P531.		5
57	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimer's and Dementia, 2013, 9, 602-608.	0.8	292
58	The Impact of AD Drug Treatments on Event-Related Potentials as Markers of Disease Conversion. Current Alzheimer Research, 2013, 10, 732-741.	1.4	2
59	The Law of Diminishing Intent: Getting Excited About Apathy. Journal of Clinical Psychiatry, 2013, 74, 817-818.	2.2	0
60	Depression and Risk of Dementia: Exploring the Interface. Journal of Clinical Psychiatry, 2013, 74, 1262-1263.	2.2	0
61	Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, 261-271.	0.8	240
62	Citalopram for agitation in Alzheimer's disease: Design and methods. Alzheimer's and Dementia, 2012, 8, 121-130.	0.8	45
63	Personality Factors Moderate the Associations Between Apolipoprotein Genotype and Cognitive Function as Well as Late Onset Alzheimer Disease. American Journal of Geriatric Psychiatry, 2012, 20, 1026-1035.	1.2	33
64	Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease. American Journal of Geriatric Psychiatry, 2012, 20, 1036-1044.	1.2	41
65	C145 as a Short-Latency Electrophysiological Index of Cognitive Compensation in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 55-68.	2.6	14
66	Novel Therapeutics in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-2.	2.0	2
67	Gene by neuroticism interaction and cognitive function among older adults. International Journal of Geriatric Psychiatry, 2012, 27, 1147-1154.	2.7	14
68	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurology, The, 2012, 11, 241-249.	10.2	390
69	Depression in Older Adults. Journal of Clinical Psychiatry, 2012, 73, 113-114.	2.2	0
70	Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences. Journal of Geriatric Psychiatry and Neurology, 2011, 24, 222-228.	2.3	14
71	Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 187-199.	1.3	87
72	Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study (DIADS-2)? International Journal of Geriatric Psychiatry, 2011, 26, 573-583.	2.7	49

#	ARTICLE	IF	CITATIONS
73	Memantine: a treatment for Alzheimer's disease with a new formulation. <i>Aging Health</i> , 2011, 7, 349-362.	0.3	3
74	Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2011, 68, 853.	12.3	183
75	Sertraline for the Treatment of Depression in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 136-145.	1.2	199
76	Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 332-340.	1.2	151
77	Diagnosis of Alzheimer's disease using neuropsychological testing improved by multivariate analyses. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2010, 32, 793-808.	1.3	44
78	Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related Disorders. <i>Biological Psychiatry</i> , 2010, 67, 505-512.	1.3	565
79	Depression Predicts Cognitive Disorders in Older Primary Care Patients. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 74-79.	2.2	33
80	Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 752-759.	1.2	46
81	Grumpy Old Men (and Women): Mere Hassle or Meaningful Clinical Evidence?. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 582-583.	2.2	0
82	A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 537-550.	1.2	95
83	Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Current Alzheimer Research</i> , 2008, 5, 83-89.	1.4	244
84	Memantine in the treatment of mild-to-moderate Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 203-214.	1.8	49
85	Donepezil in the treatment of severe Alzheimer's disease. <i>Aging Health</i> , 2007, 3, 419-435.	0.3	0
86	Divalproex Sodium for the Treatment of Behavioural Problems Associated With Dementia in the Elderly. <i>Drugs and Aging</i> , 2006, 23, 877-886.	2.7	25
87	Design of Depression in Alzheimer's Disease Study-2. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 920-930.	1.2	34
88	Memantine in the treatment of Alzheimer's disease. <i>Aging Health</i> , 2006, 2, 891-904.	0.3	1
89	Drug Treatment: Memantine. , 2006, , 123-130.		0
90	Clinical application of operationalized criteria for "Depression of Alzheimer's Disease". <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 119-127.	2.7	38

#	ARTICLE	IF	CITATIONS
91	A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Safety and Tolerability of Two Doses of Divalproex Sodium in Outpatients with Probable Alzheimers Disease. <i>Current Alzheimer Research</i> , 2005, 2, 553-558.	1.4	39
92	Divalproex Sodium in Nursing Home Residents With Possible or Probable Alzheimer Disease Complicated by Agitation. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 942-949.	1.2	15
93	Divalproex Sodium in Nursing Home Residents With Possible or Probable Alzheimer Disease Complicated by Agitation: A Randomized, Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 942-949.	1.2	91
94	Therapeutic strategies for psychosis associated with alzheimer disease. <i>Current Psychosis & Therapeutics Reports</i> , 2004, 2, 116-120.	0.1	0
95	Dementia Management: Regulations, Rules, and Research. <i>Journal of the American Medical Directors Association</i> , 2003, 4, H13-H16.	2.5	2
96	Valproate Therapy for Agitation in Dementia: Open-Label Extension of a Double-Blind Trial. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 434-440.	1.2	36
97	Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 434-40.	1.2	15
98	Mood stabilizers in Alzheimerâ€™s disease: symptomatic and neuroprotective rationales. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1567-1577.	13.7	72
99	Placebo-Controlled Study of Divalproex Sodium for Agitation in Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2001, 9, 58-66.	1.2	142
100	Pharmacologic therapy for behavioral symptoms of alzheimer's disease. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 359-376.	2.6	31
101	Second Generation Anticonvulsant Medications: Their Use in Children. <i>Journal of School Nursing</i> , 2001, 17, 103-111.	1.4	3
102	Reconsidering the DSM-IV Diagnoses of Alzheimer's Disease: Behavioral and Psychological Symptoms in Patients With Dementia. <i>International Psychogeriatrics</i> , 2000, 12, 23-27.	1.0	3
103	Anticonvulsants to Treat Agitation in Dementia. <i>International Psychogeriatrics</i> , 2000, 12, 237-244.	1.0	3
104	An Open Trial of Valproate for Agitation in Geriatric Neuropsychiatric Disorders. <i>American Journal of Geriatric Psychiatry</i> , 1997, 5, 344-351.	1.2	57
105	Suicide and Alcoholism. <i>American Journal on Addictions</i> , 1997, 6, 304-310.	1.4	4
106	Treating Alzheimer's disease. <i>Postgraduate Medicine</i> , 1997, 101, 73-90.	2.0	23
107	Treatment of agitation in dementia. <i>New Directions for Mental Health Services</i> , 1997, 24, 109-123.	0.4	18
108	Thyroid Evaluation of Hospitalized Psychiatric Patients: The Role of TSH Screening for Thyroid Dysfunction. <i>Thyroid</i> , 1996, 6, 451-456.	4.5	11